252 related articles for article (PubMed ID: 21687633)
21. Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.
Yan-Fang T; Zhi-Heng L; Li-Xiao X; Fang F; Jun L; Gang L; Lan C; Na-Na W; Xiao-Juan D; Li-Chao S; Wen-Li Z; Pei-Fang X; He Z; Guang-Hao S; Yan-Hong L; Yi-Ping L; Yun-Yun X; Hui-Ting Z; Yi W; Mei-Fang J; Lin L; Jian N; Shao-Yan H; Xue-Ming Z; Xing F; Jian W; Jian P
PLoS One; 2015; 10(7):e0126566. PubMed ID: 26176219
[TBL] [Abstract][Full Text] [Related]
22. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells.
Gillespie S; Borrow J; Zhang XD; Hersey P
Apoptosis; 2006 Dec; 11(12):2251-65. PubMed ID: 17051334
[TBL] [Abstract][Full Text] [Related]
23. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
Häcker S; Dittrich A; Mohr A; Schweitzer T; Rutkowski S; Krauss J; Debatin KM; Fulda S
Oncogene; 2009 Sep; 28(35):3097-110. PubMed ID: 19597472
[TBL] [Abstract][Full Text] [Related]
25. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.
Butler LM; Liapis V; Bouralexis S; Welldon K; Hay S; Thai le M; Labrinidis A; Tilley WD; Findlay DM; Evdokiou A
Int J Cancer; 2006 Aug; 119(4):944-54. PubMed ID: 16550602
[TBL] [Abstract][Full Text] [Related]
26. Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells.
Lin Z; Zhang Z; Jiang X; Kou X; Bao Y; Liu H; Sun F; Ling S; Qin N; Jiang L; Yang Y
Oncotarget; 2017 Mar; 8(11):17833-17848. PubMed ID: 28147319
[TBL] [Abstract][Full Text] [Related]
27. Low-dose combinations of LBH589 and TRAIL can overcome TRAIL-resistance in colon cancer cell lines.
Lee SC; Cheong HJ; Kim SJ; Yoon J; Kim HJ; Kim KH; Kim SH; Kim HJ; Bae SB; Kim CK; Lee N; Lee KT; Park SK; Hong DS; Park HS; Won JH
Anticancer Res; 2011 Oct; 31(10):3385-94. PubMed ID: 21965751
[TBL] [Abstract][Full Text] [Related]
28. DAPK plays an important role in panobinostat-induced autophagy and commits cells to apoptosis under autophagy deficient conditions.
Gandesiri M; Chakilam S; Ivanovska J; Benderska N; Ocker M; Di Fazio P; Feoktistova M; Gali-Muhtasib H; Rave-Fränk M; Prante O; Christiansen H; Leverkus M; Hartmann A; Schneider-Stock R
Apoptosis; 2012 Dec; 17(12):1300-15. PubMed ID: 23011180
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic silencing of apoptosis-inducing gene expression can be efficiently overcome by combined SAHA and TRAIL treatment in uterine sarcoma cells.
Fröhlich LF; Mrakovcic M; Smole C; Lahiri P; Zatloukal K
PLoS One; 2014; 9(3):e91558. PubMed ID: 24618889
[TBL] [Abstract][Full Text] [Related]
30. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
[TBL] [Abstract][Full Text] [Related]
31. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells.
Llobet D; Eritja N; Encinas M; Llecha N; Yeramian A; Pallares J; Sorolla A; Gonzalez-Tallada FJ; Matias-Guiu X; Dolcet X
Oncogene; 2008 Apr; 27(18):2513-24. PubMed ID: 17982483
[TBL] [Abstract][Full Text] [Related]
32. Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells.
Pettazzoni P; Pizzimenti S; Toaldo C; Sotomayor P; Tagliavacca L; Liu S; Wang D; Minelli R; Ellis L; Atadja P; Ciamporcero E; Dianzani MU; Barrera G; Pili R
Free Radic Biol Med; 2011 Jan; 50(2):313-22. PubMed ID: 21078383
[TBL] [Abstract][Full Text] [Related]
33. MYB down-regulation enhances sensitivity of U937 myeloid leukemia cells to the histone deacetylase inhibitor LBH589 in vitro and in vivo.
Ye P; Zhao L; McGirr C; Gonda TJ
Cancer Lett; 2014 Feb; 343(1):98-106. PubMed ID: 24075958
[TBL] [Abstract][Full Text] [Related]
34. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation.
Chuang MJ; Wu ST; Tang SH; Lai XM; Lai HC; Hsu KH; Sun KH; Sun GH; Chang SY; Yu DS; Hsiao PW; Huang SM; Cha TL
PLoS One; 2013; 8(9):e73401. PubMed ID: 24023871
[TBL] [Abstract][Full Text] [Related]
35. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy.
Thomas S; Thurn KT; Biçaku E; Marchion DC; Münster PN
Breast Cancer Res Treat; 2011 Nov; 130(2):437-47. PubMed ID: 21298336
[TBL] [Abstract][Full Text] [Related]
36. Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
Pietschmann K; Bolck HA; Buchwald M; Spielberg S; Polzer H; Spiekermann K; Bug G; Heinzel T; Böhmer FD; Krämer OH
Mol Cancer Ther; 2012 Nov; 11(11):2373-83. PubMed ID: 22942377
[TBL] [Abstract][Full Text] [Related]
37. Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.
Yerbes R; López-Rivas A
Invest New Drugs; 2012 Apr; 30(2):541-7. PubMed ID: 21107885
[TBL] [Abstract][Full Text] [Related]
38. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
[TBL] [Abstract][Full Text] [Related]
39. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G
Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508
[TBL] [Abstract][Full Text] [Related]
40. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
